These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 10775813)
1. Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection. Yamani MH; Starling RC; Pelegrin D; Platt L; Majercik M; Hobbs RE; McCarthy P; Young JB J Heart Lung Transplant; 2000 Apr; 19(4):337-42. PubMed ID: 10775813 [TBL] [Abstract][Full Text] [Related]
2. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. Meiser BM; Uberfuhr P; Fuchs A; Schulze C; Nollert G; Mair H; Martin S; Pfeiffer M; Reichenspurner H; Kreuzer E; Reichart B J Heart Lung Transplant; 1997 Aug; 16(8):795-800. PubMed ID: 9286771 [TBL] [Abstract][Full Text] [Related]
3. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854 [TBL] [Abstract][Full Text] [Related]
4. OKT3 therapy in addition to tacrolimus is associated with improved long-term function in patients with steroid refractory renal allograft rejection. Patschan D; Kribben A; Pietruck F; Lutz J; Binek M; Philipp T; Heemann U; Witzke O Nephron Clin Pract; 2006; 103(3):c94-9. PubMed ID: 16534238 [TBL] [Abstract][Full Text] [Related]
5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related]
6. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation. Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D Am J Nephrol; 1999; 19(6):634-40. PubMed ID: 10592356 [TBL] [Abstract][Full Text] [Related]
7. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. Cantarovich M; Latter DA; Loertscher R Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721 [TBL] [Abstract][Full Text] [Related]
8. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. Onsager DR; Canver CC; Jahania MS; Welter D; Michalski M; Hoffman AM; Mentzer RM; Love RB J Heart Lung Transplant; 1999 May; 18(5):448-55. PubMed ID: 10363689 [TBL] [Abstract][Full Text] [Related]
10. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. Millis JM; Bruce DS; Newell KA; Piper JB; Woodle ES; Seaman DS; Baker AL; Hart J; Dasgupta K; Thistlethwaite JR Transplant Proc; 1996 Apr; 28(2):1014. PubMed ID: 8623213 [No Abstract] [Full Text] [Related]
11. How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation. Eberhard OK; Kliem V; Oldhafer K; Schlitt HJ; Pichlmayr R; Koch KM; Brunkhorst R Transplantation; 1996 May; 61(9):1345-9. PubMed ID: 8629294 [TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of conversion to tacrolimus in heart transplant recipients with ongoing or recurrent acute cellular rejection. Skalická B; Málek I; Kubánek M; Vymětalová J; Kautzner J Physiol Res; 2010; 59(3):379-384. PubMed ID: 19681656 [TBL] [Abstract][Full Text] [Related]